BillionToOne is a molecular counter platform designed to accurately count DNA molecules to the single-count level. With a mission to detect disorders such as cystic fibrosis and sickle-cell disease, the company optimizes the signal-to-noise ratio through blood testing. The platform specializes in both prenatal and oncology divisions. BillionToOne was founded by David Tsao, Oguzhan Atay, and Sukrit Silas in 2016 and is headquartered in San Francisco, CA.
BillionToOne is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
If you own BillionToOne pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.
Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.
BillionToOne is a private company and not publicly traded.
If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.
Date | Funding Round | Funding Raised | Price per Share | Last Known Valuation |
---|---|---|---|---|
3/30/2022 | Series C | $125MM raised | $XXX.XX | $XXX.XX |
7/12/2021 | Series B-1 | $55MM raised | $XXX.XX | $XXX.XX |
3/10/2020 | Series B-2 | $16.02MM raised | $XXX.XX | $XXX.XX |
3/28/2019 | Series A-6 | $15.02MM raised | $XXX.XX | $XXX.XX |
8/22/2017 | Series A-1, A-2, A-3, A-4 and A-5 | $2.5MM raised | $XXX.XX | $XXX.XX |